Regeneron and ISA Pharmaceuticals announce Strategic Immuno-Oncology Collaboration
Regeneron Pharmaceuticals and ISA Pharmaceuticals announced a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer,…
Read More...
Read More...
